Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries

Kathy Pritchard-Jones, Rob Pieters, Gregory H Reaman, Lars Hjorth, Peter A Downie, Gabriele Calaminus, Marianne Naafs-Wilstra, Eva Stelliarova-Foucher

Research output: Contribution to journalArticleResearchpeer-review

95 Citations (Scopus)

Abstract

Cancer in children and adolescents is rate and biologically very different from cancer in adults. It accounts for 1.4 of all cancers worldwide, although this proportion rangges from 0.5 in Europe to 4.8 in Africa, largely because of differences in age, composition and life expectancy.
Original languageEnglish
Pages (from-to)e95 - e103
Number of pages9
JournalLancet Oncology
Volume14
Issue number3
DOIs
Publication statusPublished - 2013

Cite this

Pritchard-Jones, K., Pieters, R., Reaman, G. H., Hjorth, L., Downie, P. A., Calaminus, G., ... Stelliarova-Foucher, E. (2013). Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. Lancet Oncology, 14(3), e95 - e103. https://doi.org/10.1016/S1470-2045(13)70010-X
Pritchard-Jones, Kathy ; Pieters, Rob ; Reaman, Gregory H ; Hjorth, Lars ; Downie, Peter A ; Calaminus, Gabriele ; Naafs-Wilstra, Marianne ; Stelliarova-Foucher, Eva. / Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. In: Lancet Oncology. 2013 ; Vol. 14, No. 3. pp. e95 - e103.
@article{1e060d25af0b402da4fc0006467c58fb,
title = "Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries",
abstract = "Cancer in children and adolescents is rate and biologically very different from cancer in adults. It accounts for 1.4 of all cancers worldwide, although this proportion rangges from 0.5 in Europe to 4.8 in Africa, largely because of differences in age, composition and life expectancy.",
author = "Kathy Pritchard-Jones and Rob Pieters and Reaman, {Gregory H} and Lars Hjorth and Downie, {Peter A} and Gabriele Calaminus and Marianne Naafs-Wilstra and Eva Stelliarova-Foucher",
year = "2013",
doi = "10.1016/S1470-2045(13)70010-X",
language = "English",
volume = "14",
pages = "e95 -- e103",
journal = "Lancet Oncology",
issn = "1470-2045",
publisher = "Elsevier",
number = "3",

}

Pritchard-Jones, K, Pieters, R, Reaman, GH, Hjorth, L, Downie, PA, Calaminus, G, Naafs-Wilstra, M & Stelliarova-Foucher, E 2013, 'Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries', Lancet Oncology, vol. 14, no. 3, pp. e95 - e103. https://doi.org/10.1016/S1470-2045(13)70010-X

Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. / Pritchard-Jones, Kathy; Pieters, Rob; Reaman, Gregory H; Hjorth, Lars; Downie, Peter A; Calaminus, Gabriele; Naafs-Wilstra, Marianne; Stelliarova-Foucher, Eva.

In: Lancet Oncology, Vol. 14, No. 3, 2013, p. e95 - e103.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries

AU - Pritchard-Jones, Kathy

AU - Pieters, Rob

AU - Reaman, Gregory H

AU - Hjorth, Lars

AU - Downie, Peter A

AU - Calaminus, Gabriele

AU - Naafs-Wilstra, Marianne

AU - Stelliarova-Foucher, Eva

PY - 2013

Y1 - 2013

N2 - Cancer in children and adolescents is rate and biologically very different from cancer in adults. It accounts for 1.4 of all cancers worldwide, although this proportion rangges from 0.5 in Europe to 4.8 in Africa, largely because of differences in age, composition and life expectancy.

AB - Cancer in children and adolescents is rate and biologically very different from cancer in adults. It accounts for 1.4 of all cancers worldwide, although this proportion rangges from 0.5 in Europe to 4.8 in Africa, largely because of differences in age, composition and life expectancy.

UR - http://www.sciencedirect.com/science/article/pii/S147020451370010X

U2 - 10.1016/S1470-2045(13)70010-X

DO - 10.1016/S1470-2045(13)70010-X

M3 - Article

VL - 14

SP - e95 - e103

JO - Lancet Oncology

JF - Lancet Oncology

SN - 1470-2045

IS - 3

ER -